AZN 📈 AstraZeneca ADR - Overview

Exchange: NASDAQ • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: US0463531089

AZN: Prescription Medicines, Cancer Drugs, Cardiovascular Treatments

AstraZeneca PLC is a biopharmaceutical company that specializes in the discovery, development, manufacturing, and commercialization of prescription medicines. The company's product portfolio is diverse and extensive, with a focus on addressing various health conditions across different therapeutic areas.

In the realm of cardiovascular, renal, metabolism, and oncology, AstraZeneca's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp. These medicines are designed to improve patient outcomes and address significant unmet medical needs.

In addition to its core therapeutic areas, AstraZeneca also has a range of products for COVID-19 and rare diseases, including Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma. These products demonstrate the company's commitment to addressing emerging global health challenges and providing innovative solutions for patients with rare and debilitating conditions.

AstraZeneca's commercialization strategy involves serving primary care and specialty care physicians through a network of distributors and local representative offices across the globe, including the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. This enables the company to reach a broad patient population and make its medicines accessible to those who need them most.

The company is also engaged in various collaborations and partnerships to drive innovation and advance its pipeline. For instance, it has agreements with Neurimmune AG to develop and commercialize NI006, with BenevolentAI for drug discovery in systemic lupus erythematosus, and with Absci Corporation for AI-driven drug discovery against an oncology target. These partnerships demonstrate AstraZeneca's commitment to leveraging cutting-edge technologies and expertise to accelerate the development of new medicines.

Founded in 1992 and headquartered in Cambridge, the United Kingdom, AstraZeneca PLC has a rich history of innovation and a strong track record of delivering life-changing medicines to patients around the world. The company's website can be accessed at https://www.astrazeneca.com.

Additional Sources for AZN Stock

AZN Stock Overview

Market Cap in USD 208,361m
Sector Healthcare
Industry Drug Manufacturers - General
GiC Industry Pharmaceuticals
TER 0.00%
IPO / Inception 1993-05-12

AZN Stock Ratings

Growth 5y 62.9%
Fundamental 74.7%
Dividend 45.6%
Rel. Performance Sector -0.62
Analysts 4.5/5
Fair Price Momentum 63.25 USD
Fair Price DCF 67.24 USD

AZN Dividends

Dividend Yield 12m 2.18%
Yield on Cost 5y 3.52%
Annual Growth 5y 0.70%
Payout Consistency 96.26%

AZN Growth Ratios

Growth Correlation 3m -89.5%
Growth Correlation 12m 53.5%
Growth Correlation 5y 91.9%
CAGR 5y 10.00%
CAGR/Mean DD 5y 1.23
Sharpe Ratio 12m 0.29
Alpha -13.07
Beta 0.58
Volatility 23.02%
Current Volume 4291k
Average Volume 20d 8222.8k
What is the price of AZN stocks?
As of December 04, 2024, the stock is trading at USD 68.05 with a total of 4,291,047 shares traded.
Over the past week, the price has changed by +2.55%, over one month by -4.73%, over three months by -20.61% and over the past year by +6.92%.
Is AstraZeneca ADR a good stock to buy?
Yes, based on ValueRay Fundamental Analyses, AstraZeneca ADR (NASDAQ:AZN) is currently (December 2024) a good stock to buy. It has a ValueRay Fundamental Rating of 74.73 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AZN as of December 2024 is 63.25. This means that AZN is currently overvalued and has a potential downside of -7.05%.
Is AZN a buy, sell or hold?
AstraZeneca ADR has received a consensus analysts rating of 4.50. Therefor, it is recommend to buy AZN.
  • Strong Buy: 6
  • Buy: 3
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0
What are the forecast for AZN stock price target?
According to ValueRays Forecast Model, AZN AstraZeneca ADR will be worth about 69.1 in December 2025. The stock is currently trading at 68.05. This means that the stock has a potential upside of +1.51%.
Issuer Forecast Upside
Wallstreet Target Price 88.3 29.7%
Analysts Target Price 83.7 23%
ValueRay Target Price 69.1 1.5%